By combining appetite regulation with increased energy expenditure, retatrutide supports weight loss through two major mechanisms: Reduced caloric intake from improved satiety Increased metabolic activity that helps burn stored fat This dual action helps explain why retatrutide is often associated with more pronounced weight loss compared to therapies that rely on appetite suppression alone
They inhibit the enzyme DPP-4, thus impairing the rapid degradation of two key incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
Observational, but definitely challenges the narrative that GLP-1s worsen psychiatric outcomes
The combined effect supports weight loss and metabolic health more effectively than targeting a single pathway
The following general principles apply to subcutaneous self-injection, but you should always follow the specific instructions provided with your device and by your healthcare team, as details such as hold time, injection speed, and needle length are device-specific